Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

31.65
-0.5300-1.65%
Post-market: 32.000.3500+1.11%19:38 EDT
Volume:2.41M
Turnover:76.17M
Market Cap:2.48B
PE:-7.29
High:32.54
Open:32.26
Low:30.98
Close:32.18
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:1.22
T/O Rate:3.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:3.48
PE(LYR):-8.12

Loading ...

Celldex Therapeutics Q2 Revenue USD 22 Thousand

THOMSON REUTERS
·
Aug 07

Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus

Simply Wall St.
·
Aug 01

PharmaCyte Net Loss Widens to $19.42 Million in FY26; Revenue Remains no Revenue

Reuters
·
Jul 30

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)

TIPRANKS
·
Jul 25

U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma

Reuters
·
Jul 22

Celldex Therapeutics Shares Down 2.6% After Scrapping Development of Skin Disease Drug

THOMSON REUTERS
·
Jul 22

Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)

TIPRANKS
·
Jul 22

Celldex price target lowered to $61 from $67 at Cantor Fitzgerald

TIPRANKS
·
Jul 22

Celldex Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 22

Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)

TIPRANKS
·
Jul 22

Celldex Therapeutics Inc : Morgan Stanley Cuts Target Price to $40.00 from $44.00

THOMSON REUTERS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF)

TIPRANKS
·
Jul 22

Celldex Therapeutics Inc : Leerink Partners Cuts Target Price to $70 from $78

THOMSON REUTERS
·
Jul 22

Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating

MT Newswires Live
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Celldex Shares Fall After it Drops Skin Disease Drug Study

Reuters
·
Jul 22

Celldex to End Phase 2 Study for Skin-disease Treatment

Dow Jones
·
Jul 22

Celldex reports barzolvolimab study did not meet primary, secondary endpoints

TIPRANKS
·
Jul 22

Celldex Posts Press Release on Phase 2 Barzolvolimab Results in Prurigo Nodularis

Reuters
·
Jul 22